Skip to content

Cutaneous Melanoma Detection and Management

Most cited papers

  1. Improved Survival with Ipilimumab in Patients with Metastatic MelanomaNew England Journal of Medicine · 2010 · 15,401 citations
  2. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine · 2015 · 8,341 citations
  3. The Eighth Edition AJCC Cancer Staging Manual: Continuing to build a bridge from a population‐based to a more “personalized” approach to cancer stagingCA A Cancer Journal for Clinicians · 2017 · 6,930 citations
  4. Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations
  5. Nivolumab in Previously Untreated Melanoma without BRAF MutationNew England Journal of Medicine · 2014 · 5,648 citations
  6. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations
  7. Final Version of 2009 AJCC Melanoma Staging and ClassificationJournal of Clinical Oncology · 2009 · 4,656 citations
  8. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic MelanomaNew England Journal of Medicine · 2011 · 4,600 citations
  9. Technical Details of Intraoperative Lymphatic Mapping for Early Stage MelanomaArchives of Surgery · 1992 · 4,357 citations
  10. Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine · 2014 · 4,349 citations
  11. Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations

Metadata from OpenAlex (CC0).